Registered:
4/06/09
Seen:
13th Aug
Followers:
1029

Documents
7044

Occupation: Research House

Interests: Stocks

Twitter: Edison_Inv_Res

About Me:

Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.

Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.

Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).



Investment Research

Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.

Web Address: http://www.edisongroup.com

Address: 280 High Holborn
London
WC1V 7EE

Tel: Tel: +44 (0)20 3077 5700

Find out More »


Edison Investment Research's Latest Blogs

Paion’s Japanese partner, Ono, intends to delay approval filing of short acting sedative remimazolam until it decides on a course of action following the unclear outcome from dose-finding studies in ICU sedation, a secondary indication. Paion does not expect this to affect the approval process in lead European and US indications of general anaesthesia and procedural sedation. We have lowered our valuation to €170m from…

Norwegian financial group Ferd has agreed to invest $23m at a subscription price of NOK4.00 for 7.3% of Thinfilm’s shares. It has also been granted three-year options to acquire a further 6.1% after 12 months at an exercise price of NOK4.80, which would raise an additional $23m. If approved at an upcoming EGM, this placing combined with the exercise of options should provide Thinfilm with…

Medcom Tech is on target to achieve 19% reported sales growth in FY14 in the core orthopaedics business, supporting investment into its subsidiaries. An innovative video-monitored laryngeal mask – TotalTrack VLM – was launched in Europe in July by Medcom Flow and will be rolled out in the US in H214. Meanwhile, Medcom Advance is due to unveil an instantaneous virus detection tool in H115.…

The acquisition of Aciex in the US (for $65m in shares upfront plus up to $55m in contingent value rights), pending shareholder approval at the EGM on 22 October, represents a significant move in Nicox's strategy to transform into an international ophthalmic player. Recent positive Phase III data for VESNEO should allow filing in Q215 and a 2016 entry into the $2bn US glaucoma market.…

Prosensa has submitted the first module (>15,000 pages) of its rolling NDA (New Drug Application) for drisapersen for the treatment of Duchenne muscular dystrophy (DMD). Fast Track designation, coupled with the positive feedback from the FDA for an accelerated approval pathway, allows filing based on existing data with two confirmatory post-approval studies as soon as practicable. The rolling submission should be completed before end-2014, with…



Edison Investment Research's Top Awards 25



Edison Investment Research Followers

Edison Investment Research has 1029 followers including:


and 1021 more.